Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection clinical trials

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

This study looks at a new way to treat HER2-positive breast cancer that has come back locally or spread. It tests a two-step treatment: first, a medicine called T-DXd, followed by another medicine combo, PHESGO, to see how well they work.